ACURX PHARMACEUTICALS, INC.
Profile
Company Names
ACURX PHARMACEUTICALS, INC.
ACURX PHARMACEUTICALS, LLC
Addresses
259 LIBERTY AVENUE, STATEN ISLAND, NY 10305
22 CAMELOT COURT, WHITE PLAINS, NY 10603
Phone Numbers
917-533-1469
914-949-3898
Entity Type:
CORPORATION
Industry:
PHARMACEUTICALS, BIOTECHNOLOGY
Year Incorporated:
2017
State Incorporated:
DELAWARE
Total Amount Raised:
$22,644,246.00
Number of Funding Rounds:
7
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
7
2026-04-15
$4,587,473.00
$4,587,473.00
$0.00
6
2025-06-17
$3,978,664.00
$3,978,664.00
$0.00
5
2025-05-08
$0.00
$12,000,000.00
$12,000,000.00
Equity
4
2025-03-10
$3,376,350.00
$3,376,350.00
$0.00
3
2025-01-07
$2,404,259.00
$2,404,259.00
$0.00
2
2020-01-06
$455,000.00
$6,000,000.00
$5,545,000.00
Equity
1
2018-03-20
$7,842,500.00
$7,842,500.00
$0.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
ROBERT
J.
DELUCCIA
DIRECTOR, EXECUTIVE OFFICER
MICHAEL
DUFFY
DIRECTOR
STRATEGIC GLOBAL BALANCED TRUST
| FOUNDRY FUND LLC
| STRATEGIC FUNDS SPC
| STRATEGIC GLOBAL BALANCED INSTITUTIONAL TRUST I
| STRATEGIC PRIVATE EQUITY FUND III LP
| STRATEGIC INSTITUTIONAL FUNDS SPC
| STRATEGIC PORTFOLIOS (RESTRICTED) LTD SPC
| STRATEGIC HIGH YIELD TRUST
| STRATEGIC US EQUITY TRUST
| STRATEGIC INTERNATIONAL EQUITY TRUST
| SIM HEDGED STRATEGIES TRUST
| HSP INTERNATIONAL, INC.
| STRATEGIC PRIVATE EQUITY FUND IV, L.P.
| DIPEXIUM PHARMACEUTICALS, LLC
| CYLENT SYSTEMS, INC.
| STRATEGIC NON-CORE EMERGING MARKETS EQUITY TRUST
| BARKLY PROTECTS, INC.
| CITYBASE. INC.
| CITYBASE, INC.
| KANSAS CITY SOCIAL INVESTMENT POOL, LLC
| ACURX PHARMACEUTICALS, LLC
| THORNTON RISING, LLC
| CHICAGO MODEL 1, LLC
| NEWBOLD HOLDINGS GROUP, LLC
THOMAS
HARRISON
DIRECTOR
DAVID
LUCI
DIRECTOR
DAVID
P.
LUCI
DIRECTOR, EXECUTIVE OFFICER
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
PHARMACEUTICALS
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2025-05-08
